Opto Eurocor Healthcare, a subsidiary of Opto Circuits (India), launched its first Sirolimus Drug Eluting Stent (DES), E-MAGIC Plus on receipt of Drug Controller General of India (DCGI) license to sell and market the product in India.
E-MAGIC Plus consists of a balloon-expandable intra coronary cobalt chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC Plus stent releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. E-MAGIC Plus stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.
The DES market has two major drug categories: Sirolimus and Paclitaxel. Stents coated with Sirolimus and its derivatives have an immunosuppressive nature and is quite effective in treating difficult lesions. In India, Sirolimus-based angioplasty devices have a more than 90 per cent market share.
With the launch of E-MAGIC Plus, Opto Circuits becomes one of the few global players to offer DES products with a choice of two drug coatings.
The Sirolimus DES market is estimated to be worth Rs 800 crore in India”, said Vinod Ramnani, Chairman and Managing Director, Opto Circuits (India). “E-MAGIC Plus has been developed indigenously in India and with the DCGI mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East. We trust that E-MAGIC Plus will offer better treatment options and significant therapeutic advantages for the patients,” he further added.
Opto Eurocor Healthcare will launch E-MAGIC Plus in the European and Latin-American market after receiving the necessary approvals.
EH News Bureau
- Advertisement -
